PRKAB1 and prostate carcinoma: In prostate cancer, high-level amplification of PRKAB1, PRKAB2, PRKAG2, and PRKAG3 occurs in up to 6.3%, 6.8%, 4.1%, and 2% of cases respectively (Tables S1–S3).